Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

6.7%

1 terminated/withdrawn out of 15 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

47%

7 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed trials have results

Key Signals

3 recruiting2 with results

Enrollment Performance

Analytics

Phase 3
6(46.2%)
Phase 1
5(38.5%)
Phase 4
1(7.7%)
N/A
1(7.7%)
13Total
Phase 3(6)
Phase 1(5)
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials
NCT06523400Phase 3Recruiting

The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2

Role: lead

NCT04690556Phase 3Completed

Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

Role: lead

NCT06549400Phase 3Enrolling By Invitation

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.

Role: lead

NCT07097701Phase 3Recruiting

An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR

Role: lead

NCT07154654Recruiting

Prospective, Long Term, Observational Study (Patient Registry) of Paediatric Myotonic Disorders

Role: lead

NCT04622553Not ApplicableActive Not Recruiting

Open-label Extension Study in Paediatric Patients Who Have Completed the MEX-NM-301 Study.

Role: lead

NCT04616807Active Not Recruiting

An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders

Role: lead

NCT04624750Phase 3Completed

Open Label Study in Adolescents and Children With Myotonic Disorders

Role: lead

NCT04700046Phase 3Withdrawn

Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2

Role: lead

NCT05187858Phase 1Completed

A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

Role: lead

NCT03511378Phase 4Completed

Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer

Role: lead

NCT02174237Phase 1Completed

A Study to Test the Safety/Tolerability of Increasing Doses of LNP1892 Versus Placebo in Healthy Male/Female Subjects

Role: lead

NCT01717235Phase 1Completed

Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fasting Conditions

Role: lead

NCT01714856Phase 1Completed

Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fed Conditions

Role: lead

NCT01712568Phase 1Completed

Two Way Cross Over BE Fasting Pilot Study of Ropinirole Hydrochloride CR 2mg Tablets

Role: lead

All 15 trials loaded